LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Compound Discovered in Florida Keys Shows Potential as Colon Cancer Treatment

By LabMedica International staff writers
Posted on 01 Nov 2010
A chemical compound made from a type of bacteria discovered in the Florida Keys (USA) by a pharmacy researcher has shown effectiveness in fighting colon cancer in preclinical research.

Writing online October 2010 in the Journal of Pharmacology and Experimental Therapeutics, scientists from the University of Florida (UF; Gainesville, USA) reported that the compound--known as largazole because it was first discovered near Key Largo--suppresses human cancer cell growth in cultures and rodent models by attacking a class of enzymes involved in the packaging and structure of DNA.

More research is needed, but scientists hope that the finding will lead to new treatments for the about 50,000 people struck with colorectal cancer each year in the United States. Researchers are enthusiastic because in addition to having the marine bacteria as a natural source of the chemical, they have been able to produce synthetically the active chemical compound extracted from the bacteria.

"It is challenging to develop natural marine products into drug therapies due to what is termed the ‘the supply problem,'” said Dr. Hendrik Luesch, an associate professor of medicinal chemistry in the UF College of Pharmacy. "We have solved the supply problem for largazole because it has a relatively simple structure, which has made it easy to reproduce in the lab.”

The Luesch lab discovered largazole while studying samples of bacteria from the Florida Keys, publishing the finding in 2008. Known as cyanobacteria, the microbes have evolved to fend off predators or deal with harsh conditions in a marine environment, employing toxins to aid their own survival. The toxins are the compounds chemists such as Dr. Luesch desire to isolate and understand in a quest to create drugs that similarly fend off invading cancers in the body.

Since the discovery, Dr. Luesch's lab determined the compound inhibits enzymes known as histone deacetylases (HDACs), which are linked to many diseases and are increasingly viewed as promising for cancer therapy. Dr. Jiyong Hong, an assistant professor of chemistry at Duke University (Durham, NC, USA), teamed with the UF researchers to chemically reproduce the compound for additional preclinical testing, which indicates it is a potent inhibitor of cancer cells that has the right characteristics to reach its intended target without the toxic side effects of many cancer drugs.

"Knowing HDAC is the target that makes largazole effective means we can predict good drug properties because there are already two anticancer products on the market that work this way,” said Dr. Luesch, who is a member of the UF Shands Cancer Center.

Three important features make this marine compound more promising than other natural products as an effective cancer-fighting drug, Dr. Luesch noted that availability of supply, knowing its mode of action, and the fact that its cellular target is already a known anticancer target known to result in the necessary selectivity for cancer cells over normal cells.

Dr. Luesch presented the study's findings September 9, 2010, at the Marine Drug Discovery Symposium in Pohang, South Korea, and later in Mid-October at the Marine Natural Products Symposium in Phuket, Thailand. The research is planned for publication in the November 2010 issue of the Journal of Pharmacology and Experimental Therapeutics.

Related Links:
University of Florida
Duke University


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel

DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Brain biomarkers of Alzheimer\'s disease can be detected as early as middle age (Photo courtesy of University of Shutterstock)

Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age

As the global population ages, Alzheimer's disease and other dementing diseases are becoming more prevalent. The disease processes leading to Alzheimer's symptoms can begin years or even decades before... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
PURITAN MEDICAL